Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

NCT00799942 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Nystagmus, Congenital
Nystagmus, Acquired
Multiple Sclerosis

Interventions

DRUG: Neramexane mesylate

Sponsor

Merz Pharmaceuticals GmbH